In their financial results for year ending 30 September 2021, Almac recorded a £58 million (8.6%) rise in turnover from £677 million in 2020 to £735 million in 2021. Pre-tax profits were recorded at £81 million, up from £64 million (27.1% increase) for the same period the previous year.
The report also detailed an increase in Almac’s average employee figures from 5466 to 5783 (5.8%) during the period of October 2020 to September 2021. Current employee numbers for the Group now sits at more than 6500 and a current global recruitment drive will increase the total number to in excess of 8000 during the next 3 years, with approximately 1000 of these new roles planned for Northern Ireland.
Privately owned Almac is committed to reinvesting all profits back into its business and today announces a £200 million global capital investment plan to meet increased client demand during the next 3 years.
Investment will take place in existing Almac locations in Northern Ireland, other sites in the UK, Europe, North America and Asia.
Almac is at the forefront of developing, manufacturing, testing and distributing essential medicines to vulnerable patients around the world.
During this financial year the group was involved in the development of over 300 life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology. Almac was also instrumental in supporting over 200 research projects for COVID-19 vaccines and treatments.
Alan Armstrong, Almac Group CEO, said: “I am hugely proud of our achievements in the last financial year. I am incredibly grateful to every one of our employees for their part in delivering these outstanding results as we continue our vital work developing life-saving and life-enhancing medicines for our clients and patients."
“Almac is committed to reinvesting all our profit back into the business to ensure we are market leading for clients and offer the best possible work environment for our people."
“For our clients, we are investing £200 million on expansion to ensure we remain the global leaders in our industry and give them, and ultimately patients across the world who receive benefit from these therapeutics, the best possible offering from Almac.”